BPC-157 for Ulcerative Colitis & Gastritis: The Evidence

BPC-157 for ulcerative colitis rests on one human trial. In 2005, a Phase II study gave 53 patients with mild to moderate UC an 80 mg BPC-157 enema (development code PL 14736) or placebo once daily for two weeks. Disease activity fell 3.2 points on the peptide and 1.6 on placebo, a difference that was not statistically significant, and the trial never appeared as a full paper (Ruenzi et al., Gastroenterology abstract, 2005). For gastritis, stomach ulcers, IBS and H. pylori there are no human trials at all. The case for BPC-157 in the gut is a rodent case, built largely by the Zagreb laboratory that discovered the peptide.

That is the short answer. The longer one matters because the regulatory picture shifted in 2026. The FDA reviewed BPC-157 specifically for ulcerative colitis, its own scientists recommended against allowing compounding, and an advisory committee then voted the other way. If you have UC, gastritis or an ulcer and you keep seeing BPC-157 recommended, this guide sorts what is known from what is assumed, condition by condition.

This page goes deep on the stomach and colon. For the general mechanism and dosing background, see our BPC-157 gut healing guide. For Crohn's disease and fistulas, see BPC-157 for Crohn's disease.

Where BPC-157 Came From, and Why the Gut Story Starts in the Stomach

BPC stands for "body protection compound," a protein that Croatian researcher Predrag Sikiric and colleagues reported isolating from human gastric juice in the early 1990s. BPC-157 is a 15-amino-acid fragment of it. A pharmaceutical company developed it for inflammatory bowel disease under the codes PL 14736 and PL-10, and the FDA lists Bepecin as another name for the same molecule.

Two properties made it interesting for gut disease. It resists digestion in human gastric juice in the test tube, which suggested it could survive the stomach. And in rats it protected the stomach, small intestine and colon from a long list of chemical injuries. Proposed mechanisms include growth-factor signaling, new blood vessel formation (angiogenesis) and nitric oxide modulation, covered in detail in our pillar guide.

The FDA's 2026 review added a sobering line: the molecular target of BPC-157 has never been identified, and dose-response relationships have not been established. In most rat studies, a dose of 10 nanograms per kilogram worked as well as 10 micrograms per kilogram, a thousandfold difference. Drug developers usually see a dose-response curve as a sign that an effect is real.

BPC-157 and Ulcerative Colitis: What Was Actually Tested

BPC-157 is unusual among research peptides because it did enter formal human development for ulcerative colitis. What happened in that program is often misreported online, so here is what the record shows, taken from the FDA's July 2026 briefing document, which reviewed every human study it could find.

The Phase I studies in healthy volunteers

Two meeting abstracts from 2002 and 2003 describe a placebo-controlled Phase I study of PL 14736 enemas in healthy men (Veljaca et al., 2002; Veljaca et al., Gut abstract, 2003). Doses ran from 0.25 to 2 mg/kg once daily for up to eight days in 24 participants who received the drug. The most common side effects were headache and flatulence.

The pharmacokinetic finding is the one that matters for anyone choosing a route. BPC-157 was not detected in blood after the enemas, or in the 2003 abstract's words, "most" samples fell below the assay's detection limit. The FDA concluded it "does not appear that BPC-157 is absorbed systemically when given as a rectal enema."

The Phase II UC trial (Ruenzi 2005)

The only controlled trial in patients was a multicenter, randomized, double-blind, placebo-controlled Phase II study published as an abstract in Gastroenterology in 2005 (Ruenzi et al., 2005). The details:

• Patients: 53 adults with mild to moderate UC, randomized 1:1. Inclusion criteria were not described.
• Treatment: 80 mg BPC-157 enema or placebo enema once daily for two weeks.
• Endpoint: change in a "Disease Activity Index" combining clinical, laboratory, endoscopic and histology findings, not further defined.
• Result: mean change of minus 3.2 points on BPC-157 and minus 1.6 on placebo. The confidence interval for the difference crossed zero, so the trial did not show a statistically clear benefit.
• Dropouts: 46 of 53 finished. Three patients on BPC-157 and two on placebo withdrew for adverse events, which the authors described as "mainly progression of UC."

No full paper followed. No Phase III trial was registered. A separate Phase I trial of oral BPC-157 tablets in healthy volunteers in Mexico (NCT02637284) was listed on ClinicalTrials.gov, but the FDA found no posted results and no publication.

The developers' own 2012 review describes BPC-157 as "efficient in therapy of inflammatory bowel disease (PL 14736) so far only tested in clinical phase II" (Sikiric et al., Current Medicinal Chemistry, 2012). That sentence is accurate about the phase and generous about the efficacy.

What the FDA concluded in 2026

The FDA evaluated BPC-157 for one use only: ulcerative colitis. Nominators had also proposed Crohn's disease, celiac disease and tendonitis, but the agency found no clinical studies in those populations to evaluate. Its conclusion on UC was direct: "At the time of this evaluation, the data available do not support the use of BPC-157 for the treatment of UC" (FDA PCAC Briefing Document, July 2026).

The agency also noted that no study had given BPC-157 to UC patients by mouth, by injection, through the nose or on the skin. Every form sold online today is therefore untested in UC. The compounding nominations even proposed a rectal suppository, which reaches only the rectum, while the trial used a liquid enema, which can travel as far as the splenic flexure.

The rat colitis evidence

Animal data are more encouraging. In rats with cysteamine-induced colitis, a chemical model that produces UC-like lesions, control animals failed to heal while BPC-157 given by injection or in drinking water healed both the colitis and a colon-to-colon surgical join (Klicek et al., J Physiol Pharmacol, 2013). In a colocutaneous fistula model, fistulas in treated rats were about 40 percent smaller from day 3 and appeared closed by day 28 (Klicek et al., 2008).

Two caveats limit these findings. Nearly all of them come from the Sikiric group in Zagreb, and independent replication in colitis models is scarce. The FDA also flagged missing histopathology in several key studies. Rodent colitis models respond to many compounds that later fail in human trials.

Evidence grade for BPC-157 in ulcerative colitis: C. One underpowered, unpublished human trial plus single-lab animal work.

BPC-157 for Gastritis

Gastritis means inflammation of the stomach lining, and it is a label for several different diseases. That matters more than any peptide.

• H. pylori gastritis: a chronic bacterial infection that causes most peptic ulcers and raises gastric cancer risk. It needs antibiotics.
• Chemical gastritis: from NSAIDs such as ibuprofen and naproxen, aspirin, alcohol or bile reflux. Removing the cause is the treatment.
• Autoimmune gastritis: the immune system attacks the acid-producing parietal cells, targeting the gastric proton pump (H+/K+ ATPase). This causes vitamin B12 and iron malabsorption, can progress to pernicious anemia, and carries a risk of gastric neuroendocrine tumors that calls for endoscopic surveillance (Lenti et al., Nature Reviews Disease Primers, 2020).

Autoimmune gastritis is the form our readers most need to know about. It is diagnosed by anti-parietal cell antibodies and biopsy, often after years of unexplained fatigue, anemia, or tingling from B12 deficiency. If you already live with one autoimmune condition, ask whether you have been screened.

What the gastritis studies show

The stomach data are the oldest and largest part of the BPC-157 literature. In rats given high-dose aspirin, indomethacin or diclofenac, BPC-157 cut the size of stomach and small-intestine lesions by more than 75 percent, whether given before or alongside the NSAID (Sikiric et al., J Physiol Paris, 1997). In rats exposed to 96 percent alcohol, it reversed stomach, esophageal and duodenal lesions and restored sphincter pressures (Becejac et al., J Physiol Pharmacol, 2018). In chronic alcohol-drinking rats, it prevented and reversed gastric lesions alongside ranitidine (Prkacin et al., J Physiol Paris, 2001).

None of these models resemble autoimmune gastritis, where T cells destroy parietal cells. None test H. pylori infection. And no study has given BPC-157 to a human with gastritis of any type.

Evidence grade for BPC-157 in gastritis: C (animal only, chemical injury models).

BPC-157 for Stomach Ulcers (Peptic Ulcer Disease)

"Anti-ulcer agent" is how the developers originally framed BPC-157, and the NSAID data above are the core of that claim. Additional rat work shows faster healing of duodenal fistulas used as an ulcer-healing model (Skorjanec et al., J Physiol Pharmacol, 2015) and protection of the esophageal and pyloric sphincters against NSAID damage (Vitaic et al., 2017).

There are still no human ulcer trials. Peptic ulcers are one of gastroenterology's solved problems: a proton pump inhibitor course heals most of them, stopping or reducing NSAIDs removes the most common cause, and eradicating H. pylori prevents recurrence. An untreated ulcer can bleed or perforate. Using a research peptide in place of that sequence trades a known cure for an unknown.

Warning signs that need same-day care

• Black, tarry stools or vomit that looks like coffee grounds
• Vomiting blood
• Sudden severe abdominal pain, especially a rigid belly
• Dizziness or fainting with abdominal symptoms

Evidence grade for BPC-157 in stomach ulcers: C.

BPC-157 for IBS: No Data

We searched for any study of BPC-157 in irritable bowel syndrome, animal or human, and found none. The FDA's literature review also found no IBS use in the clinical record.

IBS is a disorder of gut-brain signaling, visceral sensitivity and motility. The lining is not ulcerated, so the tissue-repair story that sells BPC-157 has no clear target. Online claims that it "fixes IBS" usually conflate IBS with leaky gut, IBD, or post-infectious damage.

The 2021 ACG guideline lays out what does have evidence (Lacy et al., American Journal of Gastroenterology, 2021):

• Rule out celiac disease with serology and IBD with fecal calprotectin if you have diarrhea symptoms.
• A limited trial of a low-FODMAP diet to improve global symptoms.
• Gut-directed psychotherapy, such as gut-directed hypnotherapy or CBT.
• Rifaximin for IBS with diarrhea; chloride channel and guanylate cyclase activators for IBS with constipation.

That first step matters for our readers. Symptoms labeled IBS sometimes turn out to be celiac disease or microscopic colitis. If you suspect a barrier problem, our leaky gut supplements guide covers the better-studied options.

Evidence grade for BPC-157 in IBS: no data.

BPC-157 and H. pylori

BPC-157 has no antibacterial activity in the literature and no H. pylori eradication data. We found no study, animal or human, testing it against the infection.

H. pylori treatment has improved. The 2024 ACG guideline prefers 14 days of bismuth quadruple therapy for treatment-naive patients when antibiotic resistance is unknown, with rifabutin triple therapy or vonoprazan (a potassium-competitive acid blocker) dual therapy as alternatives for people without penicillin allergy (Chey et al., American Journal of Gastroenterology, 2024). Eradication should be confirmed with a breath, stool or biopsy test afterward, because resistance is common.

The supplement with real data here is zinc carnosine. A meta-analysis of three randomized trials (396 patients) found that adding polaprezinc to standard triple therapy doubled the odds of eradication (intention-to-treat odds ratio 2.01) with no increase in side effects (Mahmoud et al., Nutrients, 2022). The authors called the evidence scarce, and none of the trials used today's preferred quadruple regimen, so this is a question for your gastroenterologist, not a substitute.

Evidence grade for BPC-157 in H. pylori: no data. Zinc carnosine as an eradication add-on: B.

Oral vs Injection BPC-157 for Gut Conditions

Route is the most argued-over question in peptide forums, and the evidence base for it in humans is close to empty.

Two practical points follow. First, if the gut is the target, oral or rectal delivery puts the peptide where the rat data suggest it acts, and the FDA judged the immune-reaction risk of oral use "likely to be low." Second, the half-life of BPC-157 in blood is short: 5.3 minutes in dogs and 15.2 minutes in rats after intravenous dosing (He et al., Frontiers in Pharmacology, 2022). Injected peptide that reaches the bloodstream is cleared quickly, and nobody has shown how much of it reaches the colon wall.

None of this establishes that oral BPC-157 works in humans. It only explains why the gut case for injections is weaker than forums suggest. Dosing ranges used in the research literature are covered in the pillar article; discuss any dosing with your doctor.

Is BPC-157 Legal in 2026? FDA and WADA Status

The regulatory status changed several times between 2023 and late 2026. Here is the sequence, verified against FDA documents where possible.

• September 2023: FDA placed BPC-157 in Category 2 of bulk drug substances, meaning it raised significant safety concerns. Licensed 503A compounding pharmacies effectively stopped making it.
• April 2026: The original nominations were withdrawn and BPC-157 moved to the FDA's "nominated but withdrawn" list. That page still states the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans" (page current as of April 22, 2026). Leaving Category 2 is not the same as reaching Category 1.
• July 23, 2026: FDA's briefing document recommended against adding BPC-157 to the 503A Bulks List, citing poor chemical characterization, immunogenicity risk, missing safety data and lack of UC efficacy. The Pharmacy Compounding Advisory Committee then voted 8 to 6, with one abstention, to recommend adding it (ABC News; McDermott Will & Schulz, July 2026).
• Now: The vote is advisory. FDA must still decide and go through notice-and-comment rulemaking, which legal analysts expect to take into 2027 or longer. As of mid-October 2026 we found no proposed rule published.

BPC-157 is not approved as a medicine in any country, according to the FDA's review. It does not appear in the European, Japanese or International Pharmacopeias. For athletes, the 2026 WADA Prohibited List names BPC-157 explicitly under class S0 (non-approved substances), banned at all times, in and out of competition.

Quality and Purity Risks

Most BPC-157 in circulation is sold as a "research chemical" or as a dietary supplement capsule, and neither channel requires drug-grade testing. The FDA's 2026 review listed the specific gaps:

• Identity: nominators could not even specify whether they meant BPC-157 free base or BPC-157 acetate, which are different active ingredients.
• Peptide-related impurities: synthesis creates truncated and altered peptide fragments that can trigger immune reactions.
• Aggregation: peptides can clump, which changes their effect and raises immune risk.
• Sterility and endotoxins: bioburden and bacterial endotoxin testing were absent from the nomination data, a serious gap for anything injected.

The FDA's adverse event database held three reports through December 2025, all with injectable products: injection-site redness and swelling, shortness of breath requiring an emergency visit, and diffuse skin and gum darkening that recurred on rechallenge with a BPC-157 and TB-500 blend. Causation is uncertain in each case, and compounders rarely report adverse events, so the true rate is unknown.

For anyone with UC on a biologic or immunosuppressant, an unsterile injection carries more risk than it would for a healthy athlete. A certificate of analysis from an independent lab, showing HPLC purity, mass spectrometry identity and endotoxin testing, is the minimum. It does not make the product proven.

Evidence-Based Alternatives for UC and the Stomach

If you are drawn to BPC-157 because you want something that heals the lining, these options carry stronger human evidence. All of them work alongside standard care.

For ulcerative colitis

Mesalamine (5-ASA), Grade A. The FDA's own review lists oral and rectal mesalamine as the approved first-line drugs for mild to moderate UC, with biologics, JAK inhibitors and S1P modulators for moderate to severe disease. Rectal mesalamine reaches the same territory the BPC-157 enema did, and it has decades of trial data behind it. Many people with left-sided UC under-use the rectal form; ask about it.

Curcumin added to mesalamine, Grade A as an add-on. In a double-blind RCT of 50 patients with active mild to moderate UC who had not responded to two extra weeks of maximum-dose mesalamine, 53.8 percent of those given 3 g/day curcumin reached clinical remission at four weeks, versus none on placebo. Endoscopic remission was 38 percent versus zero (Lang et al., Clinical Gastroenterology and Hepatology, 2015). Curcumin has mild blood-thinning effects; check with your doctor if you take anticoagulants. The full UC supplement ranking, including probiotics, vitamin D and omega-3, is in our ulcerative colitis supplements guide.

For gastritis, ulcers and the stomach lining

Zinc carnosine, Grade B. Zinc carnosine is a chelate of zinc and L-carnosine that sticks to the stomach lining. As polaprezinc, it has been prescribed as a gastric ulcer drug in Japan since 1994 (Experimental and Therapeutic Medicine review, 2021). In a randomized crossover trial in 10 healthy volunteers, indomethacin tripled gut permeability on placebo, while 37.5 mg zinc carnosine twice daily prevented any significant rise (Mahmood et al., Gut, 2007). It is the closest thing to BPC-157's "NSAID protection" claim with human data behind it. Long-term zinc can deplete copper, so discuss the dose and duration with your doctor.

B12 and iron repletion for autoimmune gastritis. This is standard care, not an add-on. Low B12 causes nerve damage that can become permanent.

L-glutamine and colostrum. These target small-bowel permeability more than the colon or stomach. See our L-glutamine for leaky gut guide for dosing and evidence. For a side-by-side of peptides and conventional gut compounds, see peptides for gut health and our KPV peptide review, which covers a peptide aimed more squarely at gut inflammation.

What to Ask Your Gastroenterologist

If you are considering BPC-157 for UC, gastritis or an ulcer, bring these questions to your appointment. A good gastroenterologist will engage with them.

1. Is my disease controlled right now? Ask for objective markers: fecal calprotectin for UC, a repeat endoscopy if symptoms persist, a breath or stool test to confirm H. pylori is gone.
2. Have we tried rectal mesalamine? For left-sided UC and proctitis, it is often the most effective step not yet taken.
3. Have I been tested for autoimmune gastritis? Anti-parietal cell antibodies, intrinsic factor antibodies, B12, ferritin.
4. What would we measure if I tried something? Agree on a baseline (calprotectin, symptom diary, CRP) so a change can be seen.
5. Are there clinical trials I qualify for? IBD trials of new agents recruit continuously and offer monitored access.

Do not stop or reduce mesalamine, a biologic, a PPI or an antibiotic course to make room for a peptide. UC flares can escalate to hospitalization, and an incompletely treated H. pylori infection can become resistant.

Drug interactions

No interaction studies exist between BPC-157 and mesalamine, biologics, thiopurines, steroids, PPIs or H. pylori antibiotics. The FDA's rat and dog toxicity data showed altered clotting times and liver enzyme changes after 28 days of intramuscular dosing, which is a reason for extra caution if you take anticoagulants or have liver disease. The Crohn's article covers IBD drug considerations in more depth.

Who Should Not Use BPC-157

Based on the gaps the FDA identified, these groups have the least margin for error:

• Pregnant or breastfeeding women: no complete reproductive toxicity studies exist.
• People with a history of cancer or high-risk polyps: BPC-157 promotes angiogenesis in animal models, and no carcinogenicity studies have been done. Long-standing UC already raises colorectal cancer risk.
• Competitive athletes: banned at all times by WADA.
• Anyone on anticoagulants or with liver disease: see the clotting and liver signals above.
• Anyone with severe UC, active bleeding or a suspected perforation: these need hospital care.

Frequently Asked Questions

Does BPC-157 work for ulcerative colitis?

There is no good human evidence that it does. The only controlled UC trial gave a BPC-157 enema to about half of 53 patients for two weeks and was reported only as a 2005 abstract. The improvement over placebo was not statistically significant, and the FDA concluded in 2026 that the data do not support its use in UC. Grade C.

Can BPC-157 help gastritis?

It protects rat stomachs from alcohol and NSAIDs, but it has never been tested in human gastritis. Gastritis caused by H. pylori or autoimmunity needs cause-specific treatment. Grade C.

Is BPC-157 good for stomach ulcers?

Rat data are strong and human data do not exist. PPIs, NSAID removal and H. pylori eradication heal most ulcers. Bleeding ulcers are emergencies.

Does BPC-157 help IBS?

No studies exist. The ACG supports a low-FODMAP trial, gut-directed psychotherapy and rifaximin for IBS with diarrhea, after ruling out celiac disease and IBD.

Can BPC-157 treat H. pylori?

No. It has no antibacterial data. Use a 14-day antibiotic regimen as recommended by your doctor, then confirm eradication.

Is BPC-157 legal in 2026?

It is not FDA-approved or approved anywhere as a drug. An FDA advisory committee voted 8 to 6 in July 2026 to recommend allowing compounding, but no final rule exists. WADA bans it at all times.

Can I take BPC-157 with mesalamine?

No interaction studies exist. Keep your prescribed medication, tell your gastroenterologist, and track objective markers such as fecal calprotectin.

Building a Gut Protocol That Fits Your Condition

BPC-157 sits at the far edge of what we cover: interesting chemistry, promising rats, and a human record that amounts to one short enema trial. For UC and the stomach, the interventions with human trials come first, and the peptide question is worth revisiting only if the FDA rulemaking and new trials change the evidence. For the broader peptide picture, see our peptides for autoimmune disease hub, and for the supplements that rank highest across conditions, our best supplements for autoimmune disease guide.

Your best next step depends on your diagnosis, your current medication and how active your disease is. Take the free 3-minute AutoimmuneFinder quiz to get an evidence-graded protocol matched to your condition and severity.

This site provides educational information only. Not medical advice. Always consult your healthcare provider before changing your treatment plan. BPC-157 is not approved by the FDA or any national regulator for human use. Do not stop or change prescribed medication without your doctor's guidance.